Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial

Hepatology

Volumn 32, Issue 1, 2000, Pages 135-138

  Di Bisceglie, Adrian M ^a   Bonkovsky, Herbert L ^b   Chopra, Sanjiv ^c   Flamm, Stephen ^d   Reddy, Rajender K ^e   Grace, Norman ^f   Killenberg, Paul ^g   Hunt, Christine ^g   Tamburro, Carlo ^h   Tavill, Anthony S ⁱ   Ferguson, Roy ⁱ   Krawitt, Edward ^j   Banner, Barbara ^b   Bacon, Bruce R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f Brigham and Women's/Faulkner Hospitals   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF LOUISVILLE   (United States)

ⁱ Mt Sinai Medical Center Cleveland   (United States)

^j UNIVERSITY OF VERMONT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; IRON;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034235427     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.8700     Document Type: Article

References (27)

1. 1. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Realdi G. Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis. J Hepatol 1992;16:273-281.
2. 2. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. HEPATOLOGY 1997;26(Suppl 1):2S-10S.
3. 3. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Ann Intern Med 1997;127:875-881.
4. 4. McHuchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
5. 5. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499.
6. 6. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Anat Pathol 1995;103:419-424.
7. 7. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996;91:1367-1373.
8. 8. Van Thiel DH, Friedlander L, Fagiuoli S, Wright H, Irish W, Gavaler JS. Response to interferon a therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-415.
9. 9. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995;108: 1104-1109.
10. 10. Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, Noguchi O, Miyake S, et al. Hepatic iron contents and response to interferon-α in patients with chronic hepatitis C. Dig Dis Sci 1996;41:989-994.
11. 11. Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, Cesana B, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997;9:497-503.
12. 12. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:123-128.
13. 13. Alter HJ, Sanchez-Pescador R, Ureda MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepatitis 1995;2:121-132.
14. 14. Shindo M, Di Bisceglie AM, Cheung L, Shih JW-K, Cristiano K, Feinstone SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-706.
15. 15. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn HV, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
16. 16. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, Follett EAC, Seed CR, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol 1995;76:1197-1204.
17. 17. Knodell RG, Ishak KG, Black C, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-434.
18. 18. Torrance J, Bothwell TH. A simple quantitative technique for measuring iron concentrations in formalizined liver samples. S Afr J Med Sci 1968;33:9-11.
19. 19. Fong T, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, Phan C, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to a-interferon in patients with chronic hepatitis C. J Hepatol 1998;28:369-374.
20. 20. Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels as indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 1995;22:268-271.
21. 21. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Fagiuoli S, Wright HI, Gasbarrini A, et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepato-Gastroenterology 1996;43:1557-1561.
22. 22. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong T. Effect of iron depletion on long-term response to interferon-α in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997;92:1831-1834.
23. 23. Fontana R, Israel J, LeClair P, Banner BF Tortorelli K, Grace N, Levine RA, et al. Iron Reduction prior to and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. HEPATOLOGY 2000;31:730-736.
24. 24. Bacon BR, Tavill AS. Hemochromatosis and the iron overload syndromes. In, Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. Saunders: Philadelphia, 1996;1439-1472.
25. 25. Feder JN, Gnirke A, Thomas W Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-407.
26. 26. Smith BC, Grove J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. HEPATOLOGY 1998;27:1695-1699.
27. 27. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, Kaserer K, Hackl F, Polli C, Steindl PE, et al. Gastroenterology 1999;116:127-134.